168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

Subjects

Subjects :

Oncology
Hematology

Details

ISSN :

09237534

Volume :

33

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........e243321f9a492de0a147ff6066dc654b

Full Text :

https://doi.org/10.1016/j.annonc.2022.07.203